---
title: "Changzhou Qianhong Biopharma Co.,Ltd. (002550.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002550.SZ.md"
symbol: "002550.SZ"
name: "Changzhou Qianhong Biopharma Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T20:35:09.042Z"
locales:
  - [en](https://longbridge.com/en/quote/002550.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002550.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002550.SZ.md)
---

# Changzhou Qianhong Biopharma Co.,Ltd. (002550.SZ)

## Company Overview

Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.qhsh.com.cn](https://www.qhsh.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.48% |  |
| Net Profit YoY | -21.80% |  |
| P/B Ratio | 3.03 |  |
| Dividend Ratio | 1.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8654015614.39 |  |
| Revenue | 1481104342.87 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.67% | B |
| Profit Margin | 21.84% | A |
| Gross Margin | 61.08% | A |
| Revenue YoY | -2.48% | D |
| Net Profit YoY | -21.80% | D |
| Total Assets YoY | 9.62% | B |
| Net Assets YoY | 6.65% | B |
| Cash Flow Margin | 132.59% | B |
| OCF YoY | -2.48% | D |
| Turnover | 0.48 | C |
| Gearing Ratio | 11.75% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Changzhou Qianhong Biopharma Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.48%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.03",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8654015614.39",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1481104342.87",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.67%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "21.84%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "61.08%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.48%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.80%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.62%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.65%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.59%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-2.48%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.75%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.04 | 63/215 | 29.14 | 26.36 | 23.38 |
| PB | 2.95 | 139/215 | 4.54 | 3.88 | 3.59 |
| PS (TTM) | 5.69 | 140/215 | 7.98 | 6.95 | 6.44 |
| Dividend Yield | 1.78% | 76/215 | 1.52% | 1.41% | 1.23% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Underweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.57 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002550.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002550.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002550.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002550.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**